Advertisement

Cigarette Smoking Predicts Differential Benefit from Naltrexone for Alcohol Dependence

      Background

      Identifying factors that modify responsiveness to pharmacotherapies for alcohol dependence is important for treatment planning. Cigarette smoking predicts more severe alcohol dependence and poorer treatment response in general. Nevertheless, there is limited research on cigarette smoking as a potential predictor of differential response to pharmacological treatment of alcoholism.

      Methods

      We examined the association between cigarette smoking and drinking outcomes in the COMBINE (Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence) study, a randomized, double-blind placebo-controlled 16-week trial comparing combinations of medications (i.e., acamprosate and naltrexone) and behavioral interventions (i.e., medical management, combined behavioral therapy) in 1383 alcohol-dependent individuals.

      Results

      Smokers (i.e., more than one half the sample) significantly differed from nonsmokers on several demographic and drinking-related variables at baseline and generally had poorer treatment outcomes than nonsmokers. However, smokers who received naltrexone had better drinking outcomes than smokers who received placebo, whereas alcohol use among nonsmokers did not vary by naltrexone assignment. This pattern of findings occurred independent of whether patients received combined behavioral intervention or medical management and remained after controlling for alcoholism typology and baseline demographic differences. Approximately 9% of smokers quit smoking, and an additional 10% reduced their cigarette intake during treatment. Reductions in smoking did not vary by treatment assignment.

      Conclusions

      These results suggest that naltrexone might be particularly beneficial for improving alcohol use outcomes in alcohol-dependent smokers.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kranzler H.R.
        • Van Kirk J.
        Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta-analysis.
        Alcohol Clin Exp Res. 2001; 25: 1335-1341
        • Pettinati H.M.
        • Rabinowitz A.R.
        Choosing the right medication for the treatment of alcoholism.
        Curr Psychiatry Rep. 2006; 8: 383-388
        • Kraemer H.C.
        • Wilson G.T.
        • Fairburn C.G.
        • Agras W.S.
        Mediators and moderators of treatment effects in randomized clinical trials.
        Arch Gen Psychiatry. 2002; 59: 877-883
        • Anton R.F.
        • Oroszi G.
        • O'Malley S.
        • Couper D.
        • Swift R.
        • Pettinati H.
        • et al.
        An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
        Arch Gen Psychiatry. 2008; 65: 135-144
        • Bogenschutz M.P.
        • Scott Tonigan J.
        • Pettinati H.M.
        Effects of alcoholism typology on response to naltrexone in the COMBINE study.
        Alcohol Clin Exp Res. 2009; 33: 10-18
        • Rubio G.
        • Ponce G.
        • Rodriguez-Jimenez R.
        • Jimenez-Arriero M.A.
        • Hoenicka J.
        • Palomo T.
        Clinical predictors of response to naltrexone in alcoholic patients: Who benefits most from treatment with naltrexone?.
        Alcohol Alcohol. 2005; 40: 227-233
        • Tidey J.W.
        • Monti P.M.
        • Rohsenow D.J.
        • Gwaltney C.J.
        • Miranda Jr, R.
        • McGeary J.E.
        • et al.
        Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.
        Alcohol Clin Exp Res. 2008; 32: 58-66
        • Ball S.
        Type A and type B alcoholism applicability across subpopulations and treatment settings.
        Alcohol Health Res World. 1996; 20: 30-35
        • Gelernter J.
        • Kranzler H.
        • Cubells J.
        Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: Population studies, and allele frequencies in alcohol- and drug-dependent subjects.
        Mol Psychiatry. 1999; 4: 476-483
        • Grant B.F.
        • Hasin D.S.
        • Chou S.P.
        • Stinson F.S.
        • Dawson D.A.
        Nicotine dependence and psychiatric disorders in the United States: Results from the national epidemiologic survey on alcohol and related conditions.
        Arch Gen Psychiatry. 2004; 61: 1107-1115
        • McKee S.A.
        • Falba T.
        • O'Malley S.S.
        • Sindelar J.
        • O'Connor P.G.
        Smoking status is a clinical indicator for alcohol misuse in US adults.
        Arch Intern Med. 2007; 167: 716-721
        • Fiore M.C.
        • Jaen C.R.
        • Baker T.B.
        • Bailey W.C.
        • Benowitz N.L.
        • Curry S.J.
        Treating Tobacco Use and Dependence, 2008 Update.
        US Department of Health and Human Services, Rockville, MD2008
        • Abrams D.B.
        • Rohsenow D.J.
        • Niaura R.S.
        • Pedrazac M.
        • Longabaugh R.
        • Beattiee M.C.
        • et al.
        Smoking and treatment outcome for alcoholics: Effects on coping skills, urge to drink, and drinking rates.
        Behav Ther. 1992; 23: 283-297
        • Hintz T.
        • Mann K.
        Long-term behavior in treated alcoholism: Evidence for beneficial carry-over effects of abstinence from smoking on alcohol use and vice versa.
        Addict Behav. 2007; 32: 3093-3100
        • King A.
        • Cao D.
        • Vanier C.
        • Wilcox T.
        Naltrexone decreases heavy drinking rates in smoking cessation treatment: An exploratory study.
        Alcohol Clin Exp Res. 2009; 33: 1044-1050
        • O'Malley S.S.
        • Krishnan-Sarin S.
        • McKee S.A.
        • Leeman R.F.
        • Cooney N.L.
        • Meandzija B.
        • et al.
        Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation.
        Int J Neuropsychopharmacol. 2009; 12: 589-597
        • Mason B.J.
        • Lehert P.
        Effects of nicotine and illicit substance use on alcoholism treatment outcomes and acamprosate efficacy.
        J Addict Med. 2009; 3: 164-171
        • Kalman D.
        • Kim S.
        • DiGirolamo G.
        • Smelson D.
        • Ziedonis D.
        Addressing tobacco use disorder in smokers in early remission from alcohol dependence: The case for integrating smoking cessation services in substance use disorder treatment programs.
        Clin Psychol Rev. 2010; 30: 12-24
        • Prochaska J.J.
        • Delucchi K.
        • Hall S.M.
        A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery.
        J Consult Clin Psychol. 2004; 72: 1144-1156
        • Baltieri D.A.
        • Daro F.R.
        • Ribeiro P.L.
        • Andrade A.G.
        Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients.
        Drug Alcohol Depend. 2009; 105: 33-41
        • Rohsenow D.J.
        • Monti P.M.
        • Colby S.M.
        • Gulliver S.B.
        • Swift R.M.
        • Abrams D.B.
        Naltrexone treatment for alcoholics: Effect on cigarette smoking rates.
        Nicotine Tob Res. 2003; 5: 231-236
        • Anton R.F.
        • O'Malley S.S.
        • Ciraulo D.A.
        • Cisler R.A.
        • Couper D.
        • Donovan D.M.
        • et al.
        Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial.
        JAMA. 2006; 295: 2003-2017
        • O'Malley S.S.
        • Froehlich J.C.
        Advances in the use of naltrexone: An integration of preclinical and clinical findings.
        Recent Dev Alcohol. 2003; 16: 217-245
        • Tonigan J.S.
        • Miller W.R.
        • Brown J.M.
        The reliability of Form 90: An instrument for assessing alcohol treatment outcome.
        J Stud Alcohol. 1997; 58: 358-364
        • Sobell L.C.
        • Sobell M.B.
        Alcohol Consumption Measures.
        National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD2003
        • Friend K.B.
        • Pagano M.E.
        Changes in cigarette consumption and drinking outcomes: Findings from Project MATCH.
        J Subst Abuse Treat. 2005; 29: 221-229
        • Miller W.R.
        • Tonigan J.S.
        • Longabaugh R.
        The Drinker Inventory of Consequences (DrInC): An Instrument for Assessing Adverse Consequences of Alcohol Abuse. National Institutes of Health, Rockville, MD1995
        • First M.B.
        • Spitzer R.L.
        • Gibbon M.
        • Williams J.B.W.
        Structured Clinical Interview for DSM-IV-TR Axis I Disorders Research Version.
        State Psychiatric Institute, New York2002
        • Skinner H.
        • Horn J.
        Alcohol Dependence Scale: User's Guide.
        Addiction Research Foundation, Toronto1984
        • Fitzmaurice G.M.
        • Laird N.M.
        • Ware J.H.
        Applied Longitudinal Analysis.
        Wiley, Hoboken, NJ2004
        • Schmidt L.G.
        • Smolka M.N.
        Results from two pharmacotherapy trials show alcoholic smokers were more severely alcohol dependent but less prone to relapse than alcoholic non-smokers.
        Alcohol Alcohol. 2007; 42: 241-246
        • Friend K.B.
        • Pagano M.E.
        Smoking cessation and alcohol consumption in individuals in treatment for alcohol use disorders.
        J Addict Dis. 2005; 24: 61-75
        • Cooney N.L.
        • Cooney J.L.
        • Perry B.L.
        • Carbone M.
        • Cohen E.H.
        • Steinberg H.R.
        • et al.
        Smoking cessation during alcohol treatment: A randomized trial of combination nicotine patch plus nicotine gum.
        Addiction. 2009; 104: 1588-1596
        • McKee S.A.
        • Harrison E.L.
        • O'Malley S.S.
        • Krishnan-Sarin S.
        • Shi J.
        • Tetrault J.M.
        • et al.
        Varenicline reduces alcohol self-administration in heavy-drinking smokers.
        Biol Psychiatry. 2009; 66: 185-190
        • Fucito L.M.
        • Toll B.A.
        • Wu R.
        • Romano D.M.
        • Tek E.
        • O'Malley S.S.
        A preliminary investigation of varenicline for heavy drinking smokers.
        Psychopharmacology. 2011; 215: 655-663
        • Johnson B.A.
        • Ait-Daoud N.
        • Akhtar F.Z.
        • Javors M.A.
        Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: A randomized controlled trial.
        Arch Intern Med. 2005; 165: 1600-1605
        • Monterosso J.R.
        • Flannery B.A.
        • Pettinati H.M.
        • Oslin D.W.
        • Rukstalis M.
        • O'Brien C.P.
        • et al.
        Predicting treatment response to naltrexone: The influence of craving and family history.
        Am J Addict. 2001; 10: 258-268
        • Rohsenow D.J.
        • Miranda Jr, R.
        • McGeary J.E.
        • Monti P.M.
        Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics.
        Exp Clin Psychopharmacol. 2007; 15: 272-281
        • Kiefer F.
        • Helwig H.
        • Tarnaske T.
        • Otte C.
        • Jahn H.
        • Wiedemann K.
        Pharmacological relapse prevention of alcoholism: Clinical predictors of outcome.
        Eur Addict Res. 2005; 11: 83-91
        • Donny E.C.
        • Caggiula A.R.
        • Weaver M.T.
        • Levin M.E.
        • Sved A.F.
        The reinforcement-enhancing effects of nicotine: Implications for the relationship between smoking, eating, and weight.
        Physiol Behav. 2011; 104: 143-148
        • Löf E.
        • Olausson P.
        • deBejczy A.
        • Stomberg R.
        • McIntosh J.M.
        • Taylor J.R.
        • et al.
        Nicotinic acetylcholine receptors in the ventral tegmental area mediate the dopamine activating and reinforcing properties of ethanol cues.
        Psychopharmacology. 2007; 195: 333-343
        • Chiamulera C.
        Cue reactivity in nicotine and tobacco dependence: A “multiple-action” model of nicotine as a primary reinforcement and as an enhancer of the effects of smoking-associated stimuli.
        Brain Res Rev. 2005; 48: 74-97
        • Trigo J.M.
        • García E.M.
        • Berrendero F.
        • Robledo P.
        • Maldonado R.
        The endogenous opioid system: A common substrate in drug addiction.
        Drug Alcohol Depend. 2010; 108: 183-194
        • Mineur Y.S.
        • Abizaid A.
        • Rao Y.
        • Salas R.
        • DiLeone R.J.
        • Gündisch D.
        • et al.
        Nicotine decreases food intake through activation of POMC neurons.
        Science. 2011; 332: 1330-1332
        • Frech T.
        • Novak K.
        • Revelo M.P.
        • Murtaugh M.
        • Markewitz B.
        • Hatton N.
        • et al.
        Low-dose naltrexone for pruritus in systemic sclerosis.
        Int J Rheumatol. 2011; 2011: 804296
        • Brown N.
        • Panksepp J.
        Low-dose naltrexone for disease prevention and quality of life.
        Med Hypotheses. 2009; 72: 333-337
        • Mannelli P.
        • Peindl K.
        • Patkar A.A.
        • Wu L.T.
        • Tharwani H.M.
        • Gorelick D.A.
        Problem drinking and low-dose naltrexone-assisted opioid detoxification.
        J Stud Alcohol Drugs. 2011; 72: 507-513
        • Smith J.P.
        • Stock H.
        • Bingaman S.
        • Mauger D.
        • Rogosnitzky M.
        • Zagon I.S.
        Low-dose naltrexone therapy improves active Crohn's disease.
        Am J Gastroenterol. 2007; 102: 820-828
        • Lee E.M.
        • Malson J.L.
        • Waters A.J.
        • Moolchan E.T.
        • Pickworth W.B.
        Smoking topography: Reliability and validity in dependent smokers.
        Nicotine Tob Res. 2003; 5: 673-679
        • Scherer G.
        Smoking behaviour and compensation: A review of the literature.
        Psychopharmacology. 1999; 145: 1-20
        • Pelucchi C.
        • Gallus S.
        • Garavello W.
        • Bosetti C.
        • La Vecchia C.
        Cancer risk associated with alcohol and tobacco use: Focus on upper aero-digestive tract and liver.
        Alcohol Res Health. 2006; 29: 193-198